Molly, Psychedelic Drug, Shows Great Promise As Mental Health Treatment, New Study Finds

A couple hours after taking his first dose of the mind-altering drug 3,4-methylenedioxy- methamphetamine, or MDMA, Bessel Van Der Kolk lay down on a couch in the presence of two psychotherapists, put on an eyeshade, and allowed himself to sink into a quiet, hypnotic state.

Van Der Kolk, one of the world’s foremost experts on trauma, had agreed to ingest the potent compound, known to generations of recreational illegal drug users by its street names “Ecstasy” or “Molly,” because he was the principal investigator in a rigorous 15-site, phase III, clinical trial. The object was to evaluate the effectiveness of MDMA-assisted psychotherapy in patients suffering from extreme Post Traumatic Stress Disorder (PTSD). As such, he’d been told, he was required to have first-hand experience with the drug.

Sign up to our newsletter and be the first to get our news and updates direct to your inbox.